万泰生物
(603392)
| 流通市值：865.68亿 | | | 总市值：865.68亿 |
| 流通股本：12.68亿 | | | 总股本：12.68亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 752,512,644.03 | 5,510,782,512.9 | 4,968,894,713.9 | 4,163,641,154.7 |
| 营业收入 | 752,512,644.03 | 5,510,782,512.9 | 4,968,894,713.9 | 4,163,641,154.7 |
| 二、营业总成本 | 672,195,652.14 | 3,878,716,787.18 | 3,075,745,677.38 | 2,242,973,767.22 |
| 营业成本 | 202,777,049.57 | 792,124,569.57 | 591,632,043.44 | 406,031,384.12 |
| 税金及附加 | 2,947,548.03 | 33,910,374.96 | 25,820,272.86 | 21,828,267.26 |
| 销售费用 | 203,521,797.98 | 1,595,094,413.98 | 1,511,179,691.84 | 1,278,541,041.36 |
| 管理费用 | 74,995,369.83 | 352,633,938.38 | 196,633,999.96 | 120,585,403.58 |
| 研发费用 | 206,734,939.77 | 1,197,930,447.47 | 812,675,493.88 | 463,430,185.38 |
| 财务费用 | -18,781,053.04 | -92,976,957.18 | -62,195,824.6 | -47,442,514.48 |
| 其中:利息费用 | 1,727,119.83 | 6,860,370.34 | 5,899,281.17 | 3,910,762.94 |
| 其中:利息收入 | 20,670,381.15 | 87,977,395.3 | 59,699,505.68 | 41,187,701.7 |
| 加:公允价值变动收益 | 3,982,807.18 | 24,657,151.78 | 17,094,946.37 | 12,302,538.45 |
| 加:投资收益 | 41,533,742.38 | 98,897,934.56 | 81,196,330.03 | 33,656,260.46 |
| 资产处置收益 | - | 221,616.08 | 176,233.71 | 304,506.23 |
| 资产减值损失(新) | -9,156,256.2 | -459,732,643.89 | -29,758,186.65 | -33,035,244.5 |
| 信用减值损失(新) | -35,022,141.98 | 22,547,590.21 | -21,546,624.37 | -47,726,626.97 |
| 其他收益 | 46,265,757.75 | 82,793,537.1 | 64,595,789.22 | 49,880,354.36 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 127,920,901.02 | 1,401,450,911.56 | 2,004,907,524.83 | 1,936,049,175.51 |
| 加:营业外收入 | 62,174.61 | 2,293,084.65 | 1,833,535.15 | 1,383,016.06 |
| 减:营业外支出 | 2,343,326.46 | 10,352,168.44 | 3,977,705.07 | 2,776,190.65 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 125,639,749.17 | 1,393,391,827.77 | 2,002,763,354.91 | 1,934,656,000.92 |
| 减:所得税费用 | -4,143,907.52 | 146,887,437.82 | 190,997,816.8 | 225,326,605.34 |
| 六、净利润 | 129,783,656.69 | 1,246,504,389.95 | 1,811,765,538.11 | 1,709,329,395.58 |
| 持续经营净利润 | 129,783,656.69 | 1,246,504,389.95 | 1,811,765,538.11 | 1,709,329,395.58 |
| 归属于母公司股东的净利润 | 125,708,151.18 | 1,247,679,723.81 | 1,808,364,213.46 | 1,702,358,148.94 |
| 少数股东损益 | 4,075,505.51 | -1,175,333.86 | 3,401,324.65 | 6,971,246.64 |
| (一)基本每股收益 | 0.1 | 0.99 | 1.43 | 1.34 |
| (二)稀释每股收益 | 0.1 | 0.99 | 1.43 | 1.34 |
| 九、综合收益总额 | 129,783,656.69 | 1,246,504,389.95 | 1,811,765,538.11 | 1,709,329,395.58 |
| 归属于母公司股东的综合收益总额 | 125,708,151.18 | 1,247,679,723.81 | 1,808,364,213.46 | 1,702,358,148.94 |
| 归属于少数股东的综合收益总额 | 4,075,505.51 | -1,175,333.86 | 3,401,324.65 | 6,971,246.64 |
| 公告日期 | 2024-04-26 | 2024-03-29 | 2023-10-28 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |